USC Schaeffer

"Although the IRA introduced sweeping changes intended to ease the burden on older Americans, insurers’ strategic responses may end up shifting costs in new and unpredictable ways," writes @ConsumerAffairs on new Schaeffer Center research. consumeraffairs.com/news/medicare-…

The U.S. could save nearly $100B in drug spending by delinking compensation to #PBMs and other middlemen from list prices, USC Schaeffer's Geoffrey Joyce argues in a new #HAScholar analysis. schaeffer.usc.edu/research/pbm-d…

Medicare's interest in limiting AMA's powerful role in setting physician pay is a welcome development, Schaeffer's Paul Ginsburg told the @nytimes. “This is kind of a dream come true for me and other people who have been raising these issues for years.” nytimes.com/2025/07/21/ups…

It will take more than tariffs alone to move drug manufacturing back to the U.S., Schaeffer Director of Health Policy Geoffrey Joyce tells @NPR. npr.org/2025/07/19/nx-…

A fair price for anti-obesity medications should reflect their underlying value. New Schaeffer Center research estimates value-based prices for GLP-1s, accounting for patients’ health gains, reduced medical spending and increased productivity. schaeffer.usc.edu/research/a-val…

While there are real problems with the US drug supply chain, pharmaceutical #tariffs alone are likely to backfire, Senior Scholar Geoffrey Joyce writes in @barronsonline. There are smarter, more targeted ways to reshore drug manufacturing, he argues. barrons.com/articles/the-u…

📢 Funding opportunity: The USC Clinical Trial Recruitment Lab is seeking proposals for tech-based approaches to tackling recruitment and retention barriers in #Alzheimers trials. Pre-proposals are due July 18. schaeffer.usc.edu/research/2025-…

As Congress continues to explore reforms to #PBM practices, this analysis from USC Schaeffer Scholars outlines how policymakers can make sure that patients would benefit. schaeffer.usc.edu/research/a-pat…

It has never been a more exciting time for #Alzheimers research, but #clinicaltrial recruitment still takes too long. Do you have a good idea? New funding opportunity at the @USCSchaeffer Clinical Trial Recruiting Laboratory. 👇 Ideas due in by July 18! #CTRL

The #Alzheimers drug development pipeline has never been more promising, writes @PhylFerrell. To seize this opportunity to advance innovation and help patients, we must ensure #ClinicalTrials are speedy, representative and robust. schaeffer.usc.edu/research/alzhe…

Trying to figure out your own risk from wildfire smoke exposure can be overwhelming, Schaeffer Sr. Scholar Wandi Bruine de Bruin told the @latimes. She recommends focusing on the most relevant data & shifting focus to simple steps to limit future exposure. latimes.com/environment/st…

How much does it cost to live with dementia? @USCAgingCog's Dr. Julie Zissimopoulos joins #DementiaMatters to discuss the U.S. Cost of Dementia Project and their 2025 report, as well as what their findings mean for individuals, care partners and public policy in the future.…

As the Trump Administration considers most-favored nation pricing, the US should confront foreign countries’ discriminatory use of QALY-based drug pricing & ensure such practices aren’t imported here, Schaeffer Scholars wrote in formal comments. schaeffer.usc.edu/research/comme…

Health insurers this week pledged to ease the burden of #PriorAuthorization, potentially reducing red tape and speeding up access to care. USC Schaeffer research shows how use of pre-treatment approvals has grown significantly in Medicare Part D. schaeffer.usc.edu/research/medic…

A troubling disconnect has emerged in America’s fight against #diabetes, Schaeffer's Jack Chapel writes. While the risks of health complications for people w/diabetes have significantly improved since the 90s, their labor market outcomes haven’t budged. schaeffer.usc.edu/research/a-dia…

“When you start cutting staff, there are going to be some shortcuts taken,” Schaeffer Sr. Scholar @ProfGenKanter told @statnews @LizzyLaw_. “You’re going to have less time to search for qualified experts. You may not have as much experience in defining what the market is.”

Our new white paper finds Part D plans are shifting more costs onto #Medicare beneficiaries as they adjust to the IRA’s new out-of-pocket cap. While the cap provides important protection, most beneficiaries won't reach the $2,000 annual limit. schaeffer.usc.edu/research/medic…

Potential pharmaceutical tariffs could hit generic drugmakers especially hard — their average net profit margins are already much lower than those of brand-name firms, according to USC Schaeffer research cited in the @WSJ. wsj.com/health/pharma/…

Stuck with a big hospital bill? Your hospital likely offers an interest-free payment plan, finds research by Schaeffer Scholar Erin Duffy cited in The Guardian. aol.co.uk/news/us-medica…

USC's Clinical Trial Recruitment Lab, our partnership with @ATRI_USC, recently convened 40 leading experts to address an urgent question: How do we accelerate recruitment of a more representative population in #Alzheimers trials? The key takeaways ⬇️ schaeffer.usc.edu/research/advan…